Takeda Signs an Exclusive License Agreement with Poseida for Novel Non-Viral In Vivo Gene Therapies

 Takeda Signs an Exclusive License Agreement with Poseida for Novel Non-Viral In Vivo Gene Therapies

Takeda Signs an Exclusive License Agreement with Poseida for Novel Non-Viral In Vivo Gene Therapies

Shots:

  • The parties will initially develop up to 6 in vivo gene therapy programs utilizing Poseida’s piggyBac, Cas-CLOVER & biodegradable nanoparticle technology for 6 liver & HSC directed indications. Takeda has an option to add 2 additional programs and is obligated to provide funding for all program’s R&D costs
  • Poseida to receive $45M up front & preclinical milestones exceeding $125M, if milestones for 6 programs are achieved. The company is also eligible for ~2.7B milestones for all 6 programs and ~$3.6B if the milestones related to the 2 optional programs are also achieved
  • Poseida will lead research activities up to candidate selection, after which Takeda will lead development & commercialization

Click here to­ read full press release/ article | Ref: PR Newswire | Image: Poseida

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post